Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study
Simlukafusp alfa (FAP-IL2v) 联合阿特珠单抗，加或不加贝伐珠单抗，用于治疗不可切除的转移性肾细胞癌：一项随机、开放标签的 Ib 期研究
期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1136/jitc-2025-012466
Perez-Gracia, Jose Luis; Mellado, Begoña; Hansen, Aaron Richard; Alonso-Gordoa, Teresa; Gomez-Roca, Carlos; Løvendahl Eefsen, Rikke; Negrier, Sylvie; Suárez, Cristina; Lee, Jae-Lyun; Hussain, Arif; Pedrazzoli, Paolo; Moreno, Victor; Rodriguez-Vida, Alejo; Sosman, Jeffrey Alan; Waddell, Tom; Bedke, Jens; Park, Se Hoon; Sznol, Mario; Spychaj, Lukasz; Andersson, Emilia; Julien-Laferriere, Alice; Cheng, Wei-Yi; Watson, Carl; Silva, Ana Patricia; Heichinger, Christian; Staedler, Nicolas; Sleiman, Nassim; Dejardin, David; Boetsch, Christophe; Evers, Stefan; Vardar, Taner; Ardeshir-Tandon, Caroline; Dorado Pérez, Jorge; Charo, Jehad; Keshelava, Nino; Kraxner, Anton; Teichgräber, Volker; Powles, Thomas
